AbCellera Biologics (ABCL) CFO acquires 37,200 shares in open-market buy

Rhea-AI Filing Summary

AbCellera Biologics Inc. Chief Financial Officer Andrew Booth purchased 37,200 Common Shares on August 14, 2026 at $10.32 per share in an open market or private transaction. Following this trade, he holds 482,800 Common Shares directly and 130,959 Common Shares indirectly, held by his spouse.

Insider Trade Summary

Net Buyer: 37,200 shares

Net Buy 2 txns

Insider Booth Andrew

Role Chief Financial Officer

Bought 37,200 shs ($384K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	37,200	$10.32	$384K
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 482,800 shares (Direct); Common Shares — 130,959 shares (Indirect, By spouse)

Key Figures

Shares purchased: 37,200 Common Shares Purchase price: $10.32 per share Direct holdings after transaction: 482,800 Common Shares +2 more

5 metrics

Shares purchased 37,200 Common Shares Common Shares purchased on August 14, 2026

Purchase price $10.32 per share Price for the 37,200 Common Shares purchased

Direct holdings after transaction 482,800 Common Shares Direct ownership reported following the purchase

Indirect holdings (spouse) 130,959 Common Shares Indirect ownership reported as held by spouse

Net buy shares 37,200 Common Shares Net-buy direction with no reported sales

Key Terms

Common Shares, indirect ownership, Purchase in open market or private transaction, nature_of_ownership

4 terms

Common Shares financial

"security_title: "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

indirect ownership financial

"ownership_type: "indirect", ownership_code: "I""

Purchase in open market or private transaction financial

"transaction_code_description: "Purchase in open market or private transaction""

nature_of_ownership financial

"nature_of_ownership: "By spouse""

FAQ

What insider transaction did ABCL CFO Andrew Booth report?

Andrew Booth reported buying 37,200 Common Shares of AbCellera Biologics Inc. on August 14, 2026 at $10.32 per share. The transaction is coded as a purchase in an open market or private transaction and increases his direct ownership position.

How many ABCL shares does Andrew Booth own after this Form 4?

After the reported transaction, Andrew Booth directly owns 482,800 Common Shares of AbCellera Biologics Inc. He also has 130,959 Common Shares reported as indirectly owned, held by his spouse, according to the Form 4 holdings information.

At what price did the ABCL CFO purchase shares on August 14, 2026?

Andrew Booth purchased 37,200 Common Shares of AbCellera Biologics Inc. at $10.32 per share on August 14, 2026. The Form 4 describes this as a purchase in open market or private transaction based on the transaction code description.

Is Andrew Booth’s spouse’s ABCL stock included in this Form 4?

Yes. The Form 4 shows an indirect holding of 130,959 Common Shares classified as owned "By spouse". This entry is labeled as indirect ownership and represents holdings attributed to his spouse rather than directly to Andrew Booth.

How many total ABCL shares did Andrew Booth buy and sell in this Form 4?

The filing reports that Andrew Booth bought 37,200 Common Shares and reported no sales. Transaction summary data shows a net-buy direction, with buyShares of 37,200 and sellShares of 0 for this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/14/2026 - 12:05 PM Accepted by SEC EDGAR 08/14/2026 - 12:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Booth Andrew

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER

(City) (State) (Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/14/2026		P	V	37,200	A	$10.32	482,800	D
Common Shares								130,959	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Tryn Stimart, attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)